Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report

Satoshi Arakawa, Akihiko Horiguchi, Hirokazu Tomishige, Norihiko Kawabe, Hidetoshi Nagata, Shin Ishihara, Masahiro Ito, Yukio Asano, Ryotaro Ito, Masashi Isetani, Kentaro Shimizu, Kenshiro Kamio, Toki Kawai, Hironobu Yasuoka, Yoshihiro Imaeda

Research output: Contribution to journalReview articlepeer-review

Abstract

Chemotherapy with TAS-102 with bevacizumab (Bmab) is a new treatment for metastatic colorectal cancer. A 67-year-old male patient with synchronous multiple liver metastases was treated with TAS-102 with Bmab as a fifth-line chemotherapy. It was demonstrated that liver metastases decreased in size by 13% by computed tomography (CT) after 3 months of TAS-102 with Bmab therapy. The Grade 3 or worst adverse event that was experienced was neutropenia. The patient was able to continue treatment with TAS-102 with Bmab for 6 months. TAS-102 with Bmab treatment was safety and efficacious as a late-line chemotherapy treatment for metastatic colorectal cancer.

Original languageEnglish
Pages (from-to)649-651
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume45
Issue number4
Publication statusPublished - 04-2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Safety and efficacy of TAS-102 with bevacizumab for the treatment of unresectable metastatic colorectal cancer-a case report'. Together they form a unique fingerprint.

Cite this